Latest Advances in Lung Cancer Research

Opdivo plus chemo reduces death risk by 43% pre-surgery in NSCLC patients, leading to FDA approval, with broad patient eligibility regardless of PD-L1 levels.

Study finds White Americans 50% more likely to receive lung cancer screenings than Black Americans; health perception influences screening likelihood.

Merck’s Keytruda reduces early-stage lung cancer recurrence by 24% post-surgery, with plans for FDA approval submission, and shows a favorable safety profile.

Canadian researchers developed IPRO, a deep learning model for lung cancer care, enhancing prognosis by analyzing pre-treatment CT scans without manual input.

The FDA rapidly approved Bristol Myers Squibb’s Opdivo for early-stage NSCLC, marking a major advancement in pre-surgical cancer treatment.

FDA skepticism challenges sintilimab’s approval for NSCLC, citing concerns over trial data exclusivity from China and its less favored endpoint of PFS.

The FDA has granted nivolumab (Opdivo) priority review as a neoadjuvant treatment for resectable NSCLC, based on promising CheckMate -816 trial results.

Lung cancer screening disparities persist for Black Americans, with USPSTF guidelines and risk models failing to adequately address racial differences in risk and diagnosis.

Moffitt Cancer Center seeks federal funding for a mobile unit to improve lung cancer screening rates, especially for marginalized communities, aiming for operational status by early 2024.

FDA grants breakthrough designation to FoundationOne Tracker, an assay for detecting MRD in cancer, aiding treatment decisions and relapse monitoring.

Medicare expands LDCT lung cancer screening eligibility, lowering age to 50 and pack-year history to 20, streamlining processes to improve early detection.

Lung cancer in never smokers presents unique molecular traits and lower mutation burdens, necessitating distinct treatment strategies and revised screening criteria.